Es Gh Treatment Regimen

---
name: es-gh-treatment-regimen
description: This skill selects the appropriate growth hormone treatment regimen for childhood cancer survivors with confirmed growth hormone deficiency. It advises using the same dosing and monitoring strategies as for individuals with GHD from the noncancer population, triggered by questions such as “What GH dose and schedule should I use for this survivor?” or “How do I determine growth hormone therapy parameters in childhood cancer?”
---

# Select growth hormone regimen for childhood cancer survivors

## STEP 1 — Gather Information
Confirm diagnosis of growth hormone deficiency via provocative testing (e.g., insulin tolerance test, glucagon) per guideline 2.3; verify at least 1 year disease‑free after completion of anticancer therapy; obtain baseline height, weight, pubertal status, and IGF‑I level; assess for contraindications (active malignancy, untreated central hypothyroidism or adrenal insufficiency, uncontrolled seizures).

## STEP 2 — Rule In / Rule Out
Rule out active malignancy or disease‑free interval <1 year; rule out untreated severe hypothyroidism or adrenal insufficiency that must be corrected before GH initiation; rule out known hypersensitivity to somatropin.

## STEP 3 — Classify or Stratify
Classify patient as eligible for GH therapy if GHD confirmed and disease‑free ≥1 year; note that dosing follows weight‑based regimens used in noncancer GHD (e.g., 0.024–0.03 mg/kg/day subcutaneously at night) and that spinal radiation may limit spinal height gain.

## STEP 4 — Decide
Initiate GH therapy using standard noncancer regimens; monitor IGF‑I every 3–6 months and adjust dose to keep IGF‑I SDS within –2 to +2 for age, sex, and pubertal status; assess growth velocity every 6 months; evaluate for slipped capital femoral epiphysis, scoliosis progression, and intracranial hypertension periodically.

## Clinical Guardrails / Mimics / Pitfalls
Do not start GH in patients with active malignancy or <1 year disease‑free; avoid exceeding IGF‑I SDS >+2 to reduce risk of adverse metabolic effects; monitor for slipped capital femoral epiphysis (especially in obese or rapidly growing adolescents) and worsening scoliosis; recognize that GH may improve limb length but not spinal height in those with spinal irradiation; ensure concomitant hormone deficiencies (TSH, ACTH, gonadotropins) are replaced.

## Concrete Clinical Example
A 12‑year‑old male survivor of medulloblastoma received 24 Gy cranial radiation, completed therapy 2 years ago, has confirmed GHD (peak GH <5 µg/L on insulin tolerance test), IGF‑I SDS –2.5, no active disease. Start GH 0.03 mg/kg/day subcutaneously at night; after 4 months IGF‑I SDS –0.8, increase to 0.035 mg/kg/day; after 6 months growth velocity 6 cm/year; monitor IGF‑I every 4 months and watch for hip pain.

**Source:** Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer, Sklar et al., Endocrine Society Clinical Practice Guideline, 2018, doi:10.1210/jc.2018-01175